BiotechTube
Home/eFFECTOR Therapeutics/Douglas Warner
DW

Douglas Warner

Former CMO

eFFECTOR Therapeutics

Therapeutic Areas

Oncology

eFFECTOR Therapeutics Pipeline

DrugIndicationPhase
ZotatifinKRAS-mutant NSCLC; ER+ Breast CancerPhase 1b/2
TomivosertibMetastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 2

Leadership Team at eFFECTOR Therapeutics

SW
Steve Worland
Former President & CEO
MB
Michael Byrnes
Former CFO
AL
Alfred L. Garfall
Board Member
View full eFFECTOR Therapeutics profile